3D graphic showing tumor-infiltrating leukocytes (TILs) and a tumor
3D graphic showing tumor-infiltrating leukocytes (TILs) and a tumor
Logo

Clinical-grade manufacturing of TILs for therapy

Automate and standardize your tumor-infiltrating lymphocyte (TIL) manufacturing workflow for TIL therapy with the CliniMACS Prodigy® Tumor-Reactive T Cell (TRT) Process. This closed and GMP-compliant system integrates all steps, from stimulation and enrichment to transduction and expansion, supporting reliable and scalable production of clinical-grade TILs.

Adoptive cell therapy with TILs is transforming treatment for solid tumors.1-3 Yet conventional TIL manufacturing remains labor-intensive, variable, and difficult to scale. With its automated, software-guided workflow, the CliniMACS Prodigy TRT Process reduces manual handling, improves reproducibility, supports GMP compliance, and brings flexibility to adapt protocols with ease.

Content overview

Content

  • Application overview
  • 1. Cell stimulation
  • 2. Separation of tumor-reactive T cells
  • 3. T cell activation
  • 4. Viral transduction
  • 5. Expansion of antigen-specific T cells
  • GMP-compliant cell sorting
  • In-process and release testing by clinical flow cytometry
  • Additional resources
  • Contact and support
Short video

Fast Facts: CliniMACS Prodigy Tumor-Reactive T Cell (TRT) Process

Watch the 10 minutes video and learn more about our clinical-scale TIL manufacturing solutions.

Five easy steps to your final TIL product

From sample input to final expansion, every step is performed within a single, automated CliniMACS Prodigy Instrument in combinatioin with the Tubing Set 520. The process is designed with built-in flexibility, allowing you to adapt each step to your specific protocol.

  • Flexible input: Tumor digest, leukapheresis product, or previously outgrown (young) TILs.
  • Customizable stimulation: Tumor digest, MACS® GMP PepTivator® Peptide Pools, or neoantigens.
  • CD137+ cell enrichment: Isolate tumor-reactive T cells when desired in the process.4,5
  • Activation: Use irradiated feeder cells for polyclonal activation or add further growth factors upon demand.
  • Transduction: Integrate viral transduction if required.
  • Direct expansion: Skip enrichment and expand previously outgrown young TILs (yTILs) using the automated rapid expansion protocol (REP).

Whether enriching CD137+ cells or expanding the bulk T cell population, the process adapts to your clinical workflow and delivers consistent performance.

Workflow overview of the Tumor Reactive T Cell (TRT) manufacturing process on the CliniMACS Prodigy
Workflow overview of the TIL manufacturing process on the CliniMACS Prodigy.
Icon selected references in turquoise
Völzke, C. et al.(2024) Front. Immunol. 15: 1483254.

Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system

This study demonstrates the feasibility of producing TILs at clinical scale using a closed, automated, and GMP-compliant system. The process offers flexibility through optional CD137+ enrichment and an automated rapid expansion protocol, enhancing consistency and clinical readiness.

Read the full article

1. Cell stimulation

Illustration of cell stimulation

Stimulation can be performed manually before loading the sample, or as the first automated step. If not required, this step can be skipped.

T cells may be activated by tumor digest or peptides (e.g., MACS GMP PepTivator Peptide Pools and neoantigens). Additionally, cytokines, such as IL-7 or IL-15 can be added.

2. Separation of tumor-reactive T cells

CD137+ cells are enriched via automated magnetic separation, reducing non-reactive bystanders and other unwanted immune cells, improving downstream expansion and transduction outcomes.

3. T cell activation

Tumor-reactive T cells are activated with MACS GMP CD3 pure antibody and irradiated feeder cells derived from autologous or allogeneic leukapheresis or PBMCs. Irradiation prevents outgrowth of the feeder cells during expansion.

4. Viral transduction

Gene modification can be performed using gamma-retroviral (RV) or lentiviral vectors (LV). MACS GMP Vectofusin®-1 enhances RV transduction efficiency and works with both static and spiculation protocols.

We also deliver tailored lentiviral solutions to meet GMP requirements.

5. Expansion of antigen-specific T cells

Expansion takes place in the built-in cell cultivation chamber within the CliniMACS Prodigy Tubing Set. Culture duration, medium exchange, and other parameters are customizable via the activity matrix.

Ideal cultivation and expansion of the cells relies on the strong synergy of MACS GMP CD3 pure antibody, TexMACS™ GMP Medium, and MACS GMP Cytokines.

Performance you can trust

Results from eight independent TIL expansions using different starting materials and tumor types demonstrate the consistency and scalability of the CliniMACS Prodigy TRT Process.

Starting materialIndication/tumor sourceStarting cell numberFinal cell number*Viability at the
end of culture [%]
Manufacturing site
Tumor digestOvarian cancer1.05 × 1052.81 × 10897.38Customer data
 Ovarian Cancer1.50 × 1051.22 × 10998.00Customer data
 Large-cell lung cancer8.00 × 1053.00 × 10992.46Miltenyi Bioindustry, Gaithersburg, US
 Melanoma5.00 × 1053.00 × 10983.23Miltenyi Biotec, Bergisch Gladbach, Germany
yTILsMelanoma1.00 × 1063.81 × 10991.33Miltenyi Biotec, Bergisch Gladbach, Germany
 Pancreatic cancer1.00 × 1065.25 × 10993.86Miltenyi Biotec, Bergisch Gladbach, Germany
 Renal cell carcinoma8.00 × 1051.94 × 10996.98Miltenyi Biotec, Bergisch Gladbach, Germany
 Urothelial carcinoma1.00 × 1063.38 × 10998.78Miltenyi Biotec, Bergisch Gladbach, Germany

*Note: The maximum cell number is limited by the cultivation chamber size of the TS 520 Tubing Set. For higher outputs, external expansion vessel integration is available.

GMP-compliant TIL sorting

As an alternative to magnetic enrichment, the MACSQuant® Tyto® Family combines effortless GMP compliance with gentle microchip-based sorting technology to efficiently sort TRTs under sterile and closed conditions. Sorted cells can then be directly expanded with the CliniMACS Prodigy TRT Process.

Workflow overview of the TIL manufacturing process inlcuding the MACSQuant Tyto Cell Sorter

Benefits:

Easy integration into GMP workflows

Ensuring safety and sterility

  • Single-use, closed cartridge-based system.
  • Aerosol-free sorting for maximum operator safety.
  • Cells are never in contact with the instrument.

Clinically proven workflow

Webinar

Harnessing the power of tumor-infiltrating lymphocytes for cell therapy

Explore the use of adoptive cell transfer therapy in the treatment of refractive metastatic melanoma. Dr Sandy Pelletier discusses her Montreal-based team’s way of overcoming the obstacles presented by using effector cells for immunotherapy.

Scientific poster

GMP-compliant sorting of antigen-specific T cells for TIL therapy

Learn how the MACSQuant Tyto Cell Sorter enables closed, GMP-compliant isolation of functional T cells for TIL manufacturing.

In-process and release testing by clinical flow cytometry

Researcher in clean room attire is starting an analysis on the flow cytometer MACSQuant Analyzer 16

In order to enable the safety and consistency of cell manufacturing, the implementation of robust in-process and release testing (IPC/RT) is crucial.

Samples collected within the manufacturing process, e.g., on the CliniMACS Prodigy, are reliably analyzed on our standardized flow cytometry platform. Our comprehensive workflow solution comprises harmonized MACSQuant Flow Cytometers, automated data acquisition and analysis (Express Modes) in an audit-ready software, and a broad portfolio of REAfinity® Recombinant Antibodies with superior specificity and reproducibility. With sensitive MHC multimers to detect antigen-specific T cells and ready-to-use staining cocktails, Miltenyi Biotec provides everything for reliable and standardized analytics.

Customized automated cell manufacturing

Every step in automated cell manufacturing on the CliniMACS Prodigy can be adapted to your specifications. In-process and quality control procedures via flow cytometry can also be tailored on a MACSQuant Analyzer using customized Express Modes for automated data analysis.

Explore your options

Explore more insights into TIL manufacturing

Webinar

Advancing clinical-grade TIL therapy manufacturing

While TILs are advancing adoptive cell therapy for solid tumors, manufacturing remains complex.
Learn how to standardize TRT production for TIL therapy in our webinar.

Webinar

Automated and streamlined manufacturing of TIL therapies

Discover how closed-system TIL manufacturing with the CliniMACS Prodigy TRT Process streamlines production. The session includes early clinical insights from liver metastases of ocular melanoma.

Scientific poster

Automated manufacturing of TRT cells for immunotherapy of glioblastoma

Learn how TRTs can be generated from glioblastoma tumor digest using the CliniMACS Prodigy TRT Process. This closed, automated workflow enables enrichment, expansion, and functional validation of CD137+ T cells, yielding memory-skewed TRTs capable of killing autologous tumor cells.

Get personalized support for your clinical-grade TIL manufacturing workflow

You have previously chosen International as your location.
What do you want to do?